BACKGROUND: There is evidence that a group of subjects with obesity fits the characteristics of metabolically healthy but obese population. We aimed to assess the prevalence of the metabolic syndrome (MS) in nondiabetic subjects with morbid obesity (body mass index (BMI) > or = 40 kg/m2) and its correlation with insulin resistance. METHODS: We analyzed the data of 211 patients (55 males and 156 females) with morbid obesity and without overt diabetes, consecutive referred for weight loss management. All subjects underwent an oral glucose tolerance test, and insulin resistance was calculated by the homeostasis model assessment (HOMA) at baseline and by the oral glucose insulin sensitivity (OGIS) during the glucose and insulin curve. Clinical and biochemical features of MS were also determined. RESULTS: The criteria for MS were fulfilled in 74% of cases, and 10 patients had obesity as the sole feature. HOMA-R was normal in 26% of cases, whereas, OGIS was normal only in three females. HOMA-R and OGIS significantly differed in relation to the presence of MS, and a trend was observed in both tests as function of the number of factors of MS (P < 0.001). At logistic regression analysis, after adjustment for age, sex, BMI at age 20 years, present BMI, and waist circumference, OGIS was the only parameter of insulin resistance significantly associated with MS (odds ratio, 2.42; 95% confidence interval, 1.63-3.60). CONCLUSIONS: A small number of metabolically healthy, but obese cases exist also in the subgroup of patients with morbid obesity in which insulin resistance maintains its pivotal role.
BACKGROUND: There is evidence that a group of subjects with obesity fits the characteristics of metabolically healthy but obese population. We aimed to assess the prevalence of the metabolic syndrome (MS) in nondiabetic subjects with morbid obesity (body mass index (BMI) > or = 40 kg/m2) and its correlation with insulin resistance. METHODS: We analyzed the data of 211 patients (55 males and 156 females) with morbid obesity and without overt diabetes, consecutive referred for weight loss management. All subjects underwent an oral glucose tolerance test, and insulin resistance was calculated by the homeostasis model assessment (HOMA) at baseline and by the oral glucose insulin sensitivity (OGIS) during the glucose and insulin curve. Clinical and biochemical features of MS were also determined. RESULTS: The criteria for MS were fulfilled in 74% of cases, and 10 patients had obesity as the sole feature. HOMA-R was normal in 26% of cases, whereas, OGIS was normal only in three females. HOMA-R and OGIS significantly differed in relation to the presence of MS, and a trend was observed in both tests as function of the number of factors of MS (P < 0.001). At logistic regression analysis, after adjustment for age, sex, BMI at age 20 years, present BMI, and waist circumference, OGIS was the only parameter of insulin resistance significantly associated with MS (odds ratio, 2.42; 95% confidence interval, 1.63-3.60). CONCLUSIONS: A small number of metabolically healthy, but obese cases exist also in the subgroup of patients with morbid obesity in which insulin resistance maintains its pivotal role.
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Rachel P Wildman; Paul Muntner; Kristi Reynolds; Aileen P McGinn; Swapnil Rajpathak; Judith Wylie-Rosett; MaryFran R Sowers Journal: Arch Intern Med Date: 2008-08-11
Authors: Antony D Karelis; David H St-Pierre; Florence Conus; Remi Rabasa-Lhoret; Eric T Poehlman Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: S Schinner; K Kempf; H Overmann; H S Willenberg; M Schott; B Rose; W A Scherbaum; C Herder Journal: Exp Clin Endocrinol Diabetes Date: 2008-09-05 Impact factor: 2.949
Authors: Elena Succurro; Maria A Marini; Simona Frontoni; Marta L Hribal; Francesco Andreozzi; Renato Lauro; Francesco Perticone; Giorgio Sesti Journal: Obesity (Silver Spring) Date: 2008-06-12 Impact factor: 5.002
Authors: Keri L Monda; Kari E North; Steven C Hunt; D C Rao; Michael A Province; Aldi T Kraja Journal: Endocr Metab Immune Disord Drug Targets Date: 2010-06 Impact factor: 2.895
Authors: M Tančić-Gajić; S Vujović; M Vukčević; M Ivović; M Drezgić; Lv Marina; M Stojanović; Z Arizanović; A Nenezić; D Micić Journal: Hippokratia Date: 2012-10 Impact factor: 0.471
Authors: Pia Pajunen; Anna Kotronen; Eeva Korpi-Hyövälti; Sirkka Keinänen-Kiukaanniemi; Heikki Oksa; Leo Niskanen; Timo Saaristo; Juha T Saltevo; Jouko Sundvall; Mauno Vanhala; Matti Uusitupa; Markku Peltonen Journal: BMC Public Health Date: 2011-10-01 Impact factor: 3.295
Authors: Francisco José Tinahones; Leticia Coín-Aragüez; Maria Dolores Mayas; Eduardo Garcia-Fuentes; Carmen Hurtado-Del-Pozo; Joan Vendrell; Fernando Cardona; Rosa-Maria Calvo; Maria-Jesus Obregon; Rajaa El Bekay Journal: BMC Physiol Date: 2012-04-02
Authors: Lara L Roberson; Ehimen C Aneni; Wasim Maziak; Arthur Agatston; Theodore Feldman; Maribeth Rouseff; Thinh Tran; Michael J Blaha; Raul D Santos; Andrei Sposito; Mouaz H Al-Mallah; Ron Blankstein; Matthew J Budoff; Khurram Nasir Journal: BMC Public Health Date: 2014-01-08 Impact factor: 3.295